Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 44 |
| Active Pipeline (Recruiting Now) | 19 (7) |
| Completed vs Stopped Early | 14 / 5 (11.4%) |
| Median Closed Actual Enrollment | 35 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Imperial College Healthcare NHS Trust | London | 15 |
| Nottingham University Hospitals NHS Trust | Nottingham, Nottinghamshire (county) | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05085028 | A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced | Phase III | RECRUITING |
| NCT04319367 | A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs). | Phase II | RECRUITING |
| NCT05889507 | Cooling in Mild Encephalopathy | Phase III | RECRUITING |
| NCT06230354 | Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis | Phase II | ACTIVE NOT RECRUITING |
| NCT03775109 | IL-1 Signal Inhibition in Alcoholic Hepatitis | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Imperial College London Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.